The Economic Times daily newspaper is available online now.

    Zydus Cadila to test ZyCoV-D on 30,000 patients in Phase-3 trials

    Synopsis

    The Ahmedabad-based company has completed dosing of Phase-2 on 1,000 participants and plans to submit data to India’s drug regulator this month.

    1Agencies
    The company expects to have final Phase-3 data by March-April 2021.
    New Delhi: Zydus Cadila is expected to test its Covid vaccine candidate, ZyCoV-D, on about 30,000 people in the Phase-3 trials that it plans to start next month.

    The Ahmedabad-based company has completed dosing of Phase-2 on 1,000 participants and plans to submit data to India’s drug regulator this month.

    Preliminary results show that it is safe as no safety concerns have been observed so far, people in the know said. “The indications are safe and the trial is under control,” one of them added.

    While the other two potential candidates being developed by Indian companies — Bharat Biotech and Serum Institute of India — are both two-dose vaccines, according to a WHO document Zydus Cadila’s candidate will be a three-dose vaccine. The company expects to have final Phase-3 data by March-April 2021.

    In an earlier interview with ET, Zydus Cadila chairman Pankaj Patel had said the company could be looking at manufacturing 100 million doses to begin with, once the vaccine received all regulatory permissions.


    (You can now subscribe to our Economic Times WhatsApp channel)
    (Catch all the Business News, Breaking News Budget 2024 News, Budget 2024 Live Coverage, Events and Latest News Updates on The Economic Times.)

    Download The Economic Times News App to get Daily Market Updates & Live Business News.

    ...more

    (You can now subscribe to our Economic Times WhatsApp channel)
    (Catch all the Business News, Breaking News Budget 2024 News, Budget 2024 Live Coverage, Events and Latest News Updates on The Economic Times.)

    Download The Economic Times News App to get Daily Market Updates & Live Business News.

    ...more
    The Economic Times

    Stories you might be interested in